Pilotto A, Franceschi M, Leandro G, Paris F, Cascavilla L, Longo M G, Niro V, Andriulli A, Scarcelli C, Di Mario F
Unità Operativa di Geriatria, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, FG, Italy.
Aliment Pharmacol Ther. 2004 Nov 15;20(10):1091-7. doi: 10.1111/j.1365-2036.2004.02246.x.
Although administration of gastroprotective drugs may reduce the risk of peptic ulcers associated with the chronic use of non-steroidal anti-inflammatory drugs or aspirin, no consensus exists as to whether this co-therapy is effective for short-term prevention, particularly in old age.
To evaluate the risk of peptic ulcer associated with acute and chronic non-steroidal anti-inflammatory drugs or aspirin therapy in elderly subjects, and the influence of antisecretory treatment on this risk.
The study included 676 elderly non-steroidal anti-inflammatory drugs or aspirin users and 2435 non-users who consecutively underwent upper gastrointestinal endoscopy. The use of non-steroidal anti-inflammatory drugs and/or aspirin as well as antisecretory drugs (H2-blockers and proton-pump inhibitors) was evaluated by a structured interview. Diagnosis of gastric and duodenal ulcer as well as Helicobacter pylori infection were carried out by endoscopy and histological examination of the gastric mucosa.
About 47.3% of patients were acute and 52.7% chronic users of non-steroidal anti-inflammatory drugs or aspirin. The risk of peptic ulcer, adjusted for age, gender, H. pylori infection and antisecretory drug use was higher in acute (gastric ulcer: odds ratio, OR = 4.47, 95% CI: 3.19-6.26 and duodenal ulcer: OR = 2.39, 95% CI: 1.73-3.31) than chronic users (gastric ulcer: OR = 2.80, 95% CI: 1.97-3.99 and duodenal ulcer: OR = 1.68, 95% CI: 1.22-2.33). Proton-pump inhibitor treatment was associated with a reduced risk of peptic ulcer in both acute (OR = 0.70, 95% CI: 0.24-2.04) and chronic (OR = 0.32, 95% CI: 0.15-0.67) non-steroidal anti-inflammatory drugs/aspirin users. Conversely, concomitant treatment with H2-blockers was associated with a significantly higher risk of peptic ulcer both in acute (OR = 10.9, 95% CI: 3.87-30.9) and chronic (OR = 6.26, 95% CI: 2.56-15.3) non-steroidal anti-inflammatory drugs/aspirin users than non-users. Proton-pump inhibitor treatment resulted in an absolute risk reduction of peptic ulcer by 36.6% in acute and 34.6% in chronic non-steroidal anti-inflammatory drugs/aspirin users; indeed, the number needed to treat to avoid one peptic ulcer in elderly non-steroidal anti-inflammatory drugs/aspirin users was three both in acute and chronic users.
These findings suggest that proton-pump inhibitor co-treatment is advisable in symptomatic elderly patients who need to be treated with non-steroidal anti-inflammatory drugs and/or aspirin for a short period of time.
尽管使用胃保护药物可能会降低与长期使用非甾体抗炎药或阿司匹林相关的消化性溃疡风险,但对于这种联合治疗在短期预防中是否有效,尤其是在老年患者中,尚无共识。
评估老年患者中与急性和慢性非甾体抗炎药或阿司匹林治疗相关的消化性溃疡风险,以及抗分泌治疗对该风险的影响。
该研究纳入了676名老年非甾体抗炎药或阿司匹林使用者以及2435名未使用者,他们均连续接受了上消化道内镜检查。通过结构化访谈评估非甾体抗炎药和/或阿司匹林以及抗分泌药物(H2受体阻滞剂和质子泵抑制剂)的使用情况。通过内镜检查和胃黏膜组织学检查诊断胃溃疡、十二指肠溃疡以及幽门螺杆菌感染。
约47.3%的患者为急性非甾体抗炎药或阿司匹林使用者,52.7%为慢性使用者。在调整年龄、性别、幽门螺杆菌感染和抗分泌药物使用情况后,急性使用者(胃溃疡:比值比,OR = 4.47,95%可信区间:3.19 - 6.26;十二指肠溃疡:OR = 2.39,95%可信区间:1.73 - 3.31)发生消化性溃疡的风险高于慢性使用者(胃溃疡:OR = 2.80,95%可信区间:1.97 - 3.99;十二指肠溃疡:OR = 1.68,95%可信区间:1.22 - 2.33)。质子泵抑制剂治疗与急性(OR = 0.70,95%可信区间:0.24 - 2.04)和慢性(OR = 0.32,95%可信区间:0.15 - 0.67)非甾体抗炎药/阿司匹林使用者消化性溃疡风险降低相关。相反,在急性(OR = 10.9,95%可信区间:3.87 - 30.9)和慢性(OR = 6.26,95%可信区间:2.56 - 15.3)非甾体抗炎药/阿司匹林使用者中,与H2受体阻滞剂联合治疗相比未使用者发生消化性溃疡的风险显著更高。质子泵抑制剂治疗使急性非甾体抗炎药/阿司匹林使用者消化性溃疡的绝对风险降低36.6%,慢性使用者降低34.6%;实际上,在老年非甾体抗炎药/阿司匹林使用者中,急性和慢性使用者避免一例消化性溃疡所需治疗的人数均为三人。
这些发现表明,对于需要短期使用非甾体抗炎药和/或阿司匹林治疗的有症状老年患者,联合使用质子泵抑制剂是可取的。